Loratadine to Test for Bone Pain From Stem Cell Mobilization in Myeloma
Tests loratadine to see if it reduces bone pain in adults with multiple myeloma.
Plain-language title generated from the registry record
Registry title: Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
Key facts
- Where
- New Brunswick, United StatesSee the 2 sites
- Phase
- Early phase 1
Where in United States
- Rutgers Cancer Institute of New JerseyNew Brunswick, United StatesTaking people
- RWJBarnabas Health - Robert Wood Johnson University Hospital, New BrunswickNew Brunswick, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rutgers, The State University of New Jersey
- Trial code
- NCT04211259
- Record updated
- 29 May 2026
- Original description
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.Read full original descriptionShow less
The Prophylactic Use of Loratadine for Granulocyte-Colony Stimulating Factor (G-CSF) Induced Bone Pain in Multiple Myeloma Patients Undergoing Stem Cell Mobilization
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization. Loratadine is an antihistamine that may help to reduce or control bone pain during the process of stem cell collection in patients with multiple myeloma.
Inclusion: Patient must be able to provide informed consent; Patients with confirmed diagnosis of multiple myeloma; Able to swallow and retain oral medication; All ethnic groups are eligible.
Exclusion: Patients undergoing haploidentical allogeneic hematopoietic stem cell transplant; On therapeutic dose of aspirin (doses greater than 81 mg) within 7 days prior to the start of the study; Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds; Any medical complications or conditions that would, in the investigator's judgement, interfere with full participation in the study; Non-English speaking person.